SeekingAlpha · Mar 5, 2026
CR
NASDAQ · CRMD
CorMedix Inc.
Healthcare · Biotechnology
$5.70
Down-$1.95 (-25.46%)
Updated Nov 1, 2026, 6:21 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 924.2M
- P/E ratio
- 5.48
- Dividend yield
- 0.00%
- 52-week range
- $5.63 – $9.09
- Volume
- 7.02M
- Avg. volume
- 2.73M
Price performance · CRMD
CRMD price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
CRMD closed at $5.70 after 20 trading sessions, down 21.56% for the selected period.
- Last close
- $5.70
- Period change
- -21.56%
- Period low
- $5.70
- Period high
- $8.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $7.68 | $7.68 | $5.63 | $5.695 | 7.02M |
| Oct 29, 2026 | $8.34 | $8.3545 | $7.455 | $7.64 | 1.89M |
| Oct 28, 2026 | $7.95 | $8.22 | $7.90 | $8.20 | 1.16M |
| Oct 27, 2026 | $7.91 | $8.11 | $7.80 | $8.00 | 1M |
| Oct 26, 2026 | $8.06 | $8.09 | $7.7622 | $7.94 | 1.13M |
| Oct 23, 2026 | $8.01 | $8.11 | $7.79 | $7.85 | 894.54K |
| Oct 22, 2026 | $7.86 | $8.12 | $7.76 | $8.10 | 1.09M |
| Oct 21, 2026 | $7.55 | $7.845 | $7.5144 | $7.79 | 1.05M |
| Oct 20, 2026 | $7.38 | $7.61 | $7.38 | $7.57 | 971.71K |
| Oct 19, 2026 | $7.26 | $7.57 | $7.25 | $7.38 | 1.47M |
| Oct 16, 2026 | $7.47 | $7.47 | $7.235 | $7.26 | 1.14M |
| Oct 15, 2026 | $7.49 | $7.695 | $7.43 | $7.46 | 1.47M |
| Oct 14, 2026 | $7.36 | $7.53 | $7.27 | $7.39 | 1.12M |
| Oct 13, 2026 | $7.43 | $7.545 | $7.33 | $7.39 | 1.42M |
| Oct 12, 2026 | $7.41 | $7.60 | $7.1568 | $7.46 | 1.59M |
| Oct 9, 2026 | $7.32 | $7.455 | $7.26 | $7.38 | 1.19M |
| Oct 8, 2026 | $7.28 | $7.36 | $7.18 | $7.32 | 1.02M |
| Oct 7, 2026 | $7.27 | $7.31 | $7.18 | $7.28 | 833.08K |
| Oct 6, 2026 | $7.38 | $7.40 | $7.125 | $7.28 | 744.26K |
| Oct 5, 2026 | $7.18 | $7.33 | $7.055 | $7.26 | 1.26M |
Latest CRMD news
The latest Smart Investors Daily articles mentioning CRMD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CRMD research
Overview
Company profile and research snapshot.
Company profile
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $19.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | Needham | Buy | — |
| Sep 23, 2026 | Oppenheimer | Outperform | — |
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
| Apr 28, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
ChartMill · Mar 5, 2026
CorMedix Inc (NASDAQ:CRMD) Shares Drop on Q4 2025 Earnings Miss
CorMedix reports strong Q4 2025 revenue growth but misses EPS estimates, leading to a sharp pre-market stock decline.
Benzinga · Mar 5, 2026
CorMedix shares are trading lower after the company reported mixed Q4 financial results.
Benzinga · Mar 5, 2026
CORRECTION: Cormedix Affirms FY2026 Sales Guidance of $300.000M-$320.000M
Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $300.000 million-$320.000 million to $300.000 million-$320.000 million.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
